Mount Yale Investment Advisors LLC Acquires 99 Shares of ResMed Inc. (NYSE:RMD)

Mount Yale Investment Advisors LLC grew its stake in ResMed Inc. (NYSE:RMD) by 2.8% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,662 shares of the medical equipment provider’s stock after purchasing an additional 99 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in ResMed were worth $725,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC bought a new stake in shares of ResMed in the 4th quarter worth $27,000. Hall Laurie J Trustee bought a new stake in shares of ResMed during the 1st quarter worth $32,000. Planned Solutions Inc. purchased a new stake in ResMed during the fourth quarter worth about $34,000. BOK Financial Private Wealth Inc. bought a new stake in shares of ResMed in the first quarter valued at $35,000. Finally, MV Capital Management Inc. increased its holdings in ResMed by 39.0% in the 4th quarter. MV Capital Management Inc. now owns 214 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 60 shares during the last quarter. 54.98% of the stock is owned by hedge funds and other institutional investors.

ResMed Stock Performance

NYSE:RMD traded up $0.76 during mid-day trading on Tuesday, hitting $209.30. 56,683 shares of the company traded hands, compared to its average volume of 1,045,738. The stock’s fifty day moving average price is $203.93 and its 200-day moving average price is $195.45. The company has a quick ratio of 1.97, a current ratio of 3.04 and a debt-to-equity ratio of 0.22. ResMed Inc. has a one year low of $132.24 and a one year high of $229.97. The firm has a market cap of $30.75 billion, a price-to-earnings ratio of 32.25, a price-to-earnings-growth ratio of 1.70 and a beta of 0.66.

Insider Activity at ResMed

In other ResMed news, CEO Michael J. Farrell sold 14,683 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $216.50, for a total value of $3,178,869.50. Following the completion of the transaction, the chief executive officer now directly owns 440,752 shares in the company, valued at $95,422,808. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Witte Jan De sold 360 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $218.29, for a total value of $78,584.40. Following the transaction, the director now directly owns 7,519 shares of the company’s stock, valued at approximately $1,641,322.51. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael J. Farrell sold 14,683 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $216.50, for a total transaction of $3,178,869.50. Following the completion of the sale, the chief executive officer now owns 440,752 shares in the company, valued at approximately $95,422,808. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,409 shares of company stock worth $9,602,796. 1.21% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on RMD shares. KeyCorp increased their target price on shares of ResMed from $227.00 to $238.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. Royal Bank of Canada raised their price target on ResMed from $200.00 to $204.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 23rd. Citigroup lowered ResMed from a “buy” rating to a “neutral” rating in a research note on Monday, June 24th. Oppenheimer downgraded ResMed from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 25th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $236.00 price target on shares of ResMed in a research report on Monday, June 24th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $203.20.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.